Schmidt Initiative for Long Covid

Name

Schmidt Initiative for Long Covid

Legal name

Schmidt Initiative for Long Covid

Website

https://silc.org

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Long Covid Clinical Care and Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Long covid research
• Clinician education
• Virtual communities of practice
• Decentralized clinical trials
• Drug repurposing research

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Philanthropic Grants and Funding: SILC is a nonprofit organization funded by philanthropists Eric and Wendy Schmidt. The organization disperses grants to partners to fortify healthcare infrastructures, improve patient care, and advance medical research. No commercial revenue streams are disclosed.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

SILC is a nonprofit organization that provides free global clinician education through Virtual Communities of Practice and a monthly Webinar Series, funds and conducts AI-driven clinical research on Long Covid pathology and drug repurposing using proteomic data from 6,000 patients, and supports decentralized clinical trials including LoCITT and the sipavibart monoclonal antibody study. The organization connects specialists at nine global hub locations with primary care providers across 123+ countries, enabling specialty consultation, case discussion, and best practice sharing for Long Covid diagnosis and treatment.

Product overview

The Schmidt Initiative for Long Covid is a nonprofit organization that offers a coordinated suite of clinical care and research programs rather than a traditional product platform. The core offerings include: (1) Virtual Communities of Practice (vCOP) - weekly Zoom-based sessions connecting specialists at global hubs with primary care providers across 82+ countries; (2) a monthly Webinar Series providing provider education with multilingual interpretation; and (3) a Clinical Research Program utilizing AI and machine learning to analyze patient proteomic data and identify drug repurposing candidates. Additionally, SILC funds and convenes clinical trials including the LoCITT platform (a decentralized digital trial powered by MyDataHelps for tirzepatide research) and the sipavibart monoclonal antibody trial. These programs work interdependently to advance Long Covid clinical care, provider education, and treatment discovery worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Virtual Communities of Practice (vCOP) Weekly virtual Zoom sessions connecting subject matter experts and clinicians to disseminate best practices, discuss Long Covid cases, and obtain specialty consultation. Links specialists at nine global hub locations with primary providers across 82+ countries.
• SILC Webinar Series Monthly educational webinars for healthcare providers worldwide covering Long Covid diagnosis, treatment, and research. Features medical and patient expert perspectives with simultaneous interpretation in Spanish, French, Arabic, Portuguese, and English.
• Clinical Research Program Global research initiative studying Long Covid symptoms and pathology using AI and machine learning to analyze proteomic and patient data from 6,000 patients, identifying FDA-approved drug repurposing candidates and patterns of disease persistence.
• Long COVID Treatment Trial (LoCITT) A novel fully remote, decentralized clinical trial platform powered by CareEvolution's MyDataHelps app that enables at-home screening, electronic consent, survey response, wearable data collection, and direct-to-home drug and placebo delivery to evaluate tirzepatide for Long Covid treatment across 1,000 U.S. participants.
• Sipavibart Long Covid Treatment Trial Double-blind, randomized, controlled clinical trial evaluating AstraZeneca's long-acting monoclonal antibody sipavibart as a potential Long Covid treatment, conducted by Nova Southeastern University researchers with SILC funding, enrolling 100 patients.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature3 records

Partnerships

20 partnerships are on record, tiered flagship and core.

• Scripps ResearchflagshipStrategic or Co-development Partner · 29 July 2025Scripps Research Translational Institute leads the LoCITT (Long Covid Treatment Trial) investigating tirzepatide as Long Covid treatment. SILC provides funding and support. Study will enroll 1,000 patients in fully remote trial.
• CareEvolutioncoreTechnology or Integration · 29 July 2025Provides MyDataHelps decentralized clinical trial platform for LoCITT. Platform enables screening, enrollment, electronic consent, data collection from wearables, and drug/placebo distribution to participants' homes.
• Nova Southeastern UniversityflagshipStrategic or Co-development Partner · 1 May 2025NSU researchers led by Dr. Nancy Klimas conduct clinical trial on sipavibart (AstraZeneca's long-acting monoclonal antibody) as Long Covid treatment. SILC provides funding. Trial enrolling 100 patients.
• Project ECHOflagshipStrategic or Co-development PartnerProject ECHO (Extension for Community Healthcare Outcomes) at University of New Mexico enables SILC's global webinar series. Project ECHO has been designated by WHO as the first Collaborating Center for Digital Learning in Health Emergencies. SILC partners with ECHO for morning and evening webinar sessions with simultaneous interpretation in 5 languages.
• Every CurecoreStrategic or Co-development PartnerEvery Cure is a nonprofit focused on drug repurposing research. They collaborate with SILC on identifying existing FDA-approved drugs that could treat Long Covid.
• World Health OrganizationflagshipStrategic or Co-development PartnerWHO is a global health leader partnering with SILC to improve Long Covid care worldwide. Project ECHO, a key SILC partner, has been designated a WHO Collaborating Center.
• Emory University Division of NeurorehabilitationcoreStrategic or Co-development PartnerLocated in Atlanta, GA, USA. Partner in clinical research and healthcare provider education for Long Covid.
• Duke UniversitycoreStrategic or Co-development PartnerLocated in Durham, NC, USA. Partner in clinical research and medical education for Long Covid. Also includes the ISLe program at Duke's Nicholas Institute for Energy, Environment & Sustainability.
• McGill UniversitycoreStrategic or Co-development PartnerLocated in Montreal, QC, Canada. Partner in clinical research collaboration for Long Covid studies.
• ECHO IndiacoreChannel Partner/ Reseller/ DistributorBased in New Delhi, India. Part of the Project ECHO network, enabling SILC's reach in South Asia with interpretation capabilities.
• Western UniversitycoreStrategic or Co-development PartnerLocated in London, ON, Canada. Partner in clinical research and drug repurposing studies for Long Covid.
• Côte d'Ivoire Ministry of Health and Public HygienecoreStrategic or Co-development PartnerBased in Abidjan, Côte d'Ivoire. Government health ministry partner working to strengthen local healthcare infrastructure and Long Covid care in West Africa.
• University of Texas Southwestern Medical SchoolcoreStrategic or Co-development PartnerLocated in Dallas, TX, USA. Partner in clinical research and medical education for Long Covid.
• Levy Mwanawasa University Teaching HospitalcoreStrategic or Co-development PartnerLocated in Lusaka, Zambia. Clinical research partner working to strengthen healthcare infrastructure and Long Covid care in Southern Africa.
• Family Health Centers of San DiegocoreStrategic or Co-development PartnerLocated in San Diego, CA, USA. Community health center partner in clinical research and healthcare delivery for underserved populations.
• Georgia Ministry of Labor, Health and Social AffairscoreStrategic or Co-development PartnerBased in Tbilisi, Georgia. Government health ministry partner for Long Covid care and research in the Caucasus region.
• Georgia National Center of Tuberculosis and Lung DiseasecoreStrategic or Co-development PartnerBased in Tbilisi, Georgia. Specialized healthcare institution partner for respiratory and infectious disease research.
• Fundação Oswaldo Cruz (Fiocruz)coreStrategic or Co-development PartnerBased in Rio de Janeiro, Brazil. Major Brazilian public health research institution partner for Long Covid clinical research in Latin America.
• Hospital de Clínicas, Facultad de Medicina, Universidad de la RepúblicacoreStrategic or Co-development PartnerBased in Montevideo, Uruguay. University medical center partner for clinical research and healthcare provider education.
• ACTION for M.E.coreStrategic or Co-development PartnerUK-based organization working on DecodeMe project for ME and Long Covid. Partner in Sequence ME & Long Covid initiative receiving major funding.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Action for ME: UK-based charity working on ME and Long Covid via the DecodeMe project, recently receiving major funding; named SILC partner for the Sequence ME & Long Covid initiative and represents a comparable national-scope nonprofit peer.
• Open Medicine Foundation: Philanthropically funded nonprofit driving collaborative research into ME/CFS and Long Covid, with multi-institution research networks and AI-driven biomarker analysis — closely mirrors SILC's research-plus-education model.
• Solve M.E. Long-standing nonprofit advocating for ME/CFS and Long Covid research funding, clinical care improvement, and patient education; structurally similar mission and beneficiary population to SILC with overlapping chronic post-infectious illness focus.
• Patient-Led Research Collaborative: Patient-led research organization conducting studies on Long Covid symptoms and treatments; operates at smaller scale than SILC but with a similar bottom-up, community-driven approach to clinical research and care improvement.
• Every Cure: Nonprofit organization focused on AI-driven drug repurposing across all FDA-approved drugs; named SILC partner for Long Covid repurposing research and operates the most directly comparable mission and methodology.
• Project ECHO: University of New Mexico-based virtual medical education network using Zoom-enabled Communities of Practice to connect specialists with primary providers worldwide — the exact operational model SILC leverages and a direct strategic partner for global webinar distribution.

Others

• Scripps Research Translational Institute: Academic research institute leading the LoCITT tirzepatide trial in partnership with SILC; while not a competing nonprofit, it operates the clinical research arm SILC funds and is the primary execution vehicle for SILC's flagship decentralized trial.

Broad incumbents

• NIH RECOVER Initiative: The largest federally-funded Long Covid research program (>1B committed), conducting observational studies, clinical trials, and pathobiology research across dozens of institutions — dwarfs SILC in scale and competes for the same research talent and patient cohorts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/schmidtinitiative

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Schmidt Initiative for Long Covid